Estimated delivery business days. Format Paperback. Condition Brand New. Description Polypharmacy practices are very common in psychiatry specially in Bangladesh. Psychiatric patients receive multiple drugs in order to have their therapeutic recovery. Both typical and atypical antipsychotic drugs are frequently prescribed by the psychiatrists.

Author:Nagul Shaktisida
Country:Saudi Arabia
Language:English (Spanish)
Published (Last):15 October 2007
PDF File Size:19.73 Mb
ePub File Size:3.22 Mb
Price:Free* [*Free Regsitration Required]

Brazilian Consensus on second-generation antipsychotics and metabolic disorders. OBJECTIVE: To discuss current aspects of use of antipsychotics considering their metabolic side effects profile, which includes weight gain, dyslipidemias, diabetes and metabolic syndrome.

Such metabolic effects increase the risk of mortality by cardiovascular disease, which is the leading cause of death among schizophrenic patients. METHOD: A consensus meeting was held, with participation of endocrinologists and psychiatrists specialists in schizophrenia and, based on a literature review, an article was elaborated emphasizing practical and helpful recommendations to clinicians.

Efficacy and tolerability should be carefully balanced in all phases of treatment. Os psiquiatras participantes eram todos especialistas em psicoses e esquizofrenia. Declarou ter recebido apoio direto ou indireto para pesquisa das seguintes companhias: Pfizer, Eli-Lilly, Acadia Pharmaceuticals e Janssen-Cilag. Fez palestras para a Astra-Zeneca e Eli-Lilly.

Walter J. Parte 1: Tratamento agudo e Parte 2: Tratamento de longo prazo. Rev Psiq Clin. J Clin Psychiatry. American Psychiatric Association. Practice guideline for the treatment of patient with schizophrenia. Am J Psychiatry. International Pharmacological Algorithm Project.

Available at: www. Chou JC-Y. Prim Psychiatry. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Prev Chronic Dis [serial online] Apr [date cited]. Consensus development conference on antipsychotic drugs and obesity Consensus Statement. Diabetes Care. Agency for Healthcare Research and Quality. Systems to rate the strength of scientific evidence. AHRQ publication no. World Health Organization. Preventing chronic diseases - a vital investment.

Obesity newsletter. Guidelines for healthy weight. N Engl J Med. Arq Bras Cardiol. Regional adiposity and morbidity. Physiol Rev. The metabolic syndrome and year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.

Emerging epidemic of type 2 diabetes in youth. Diabetes Care ;22 2 A new definition of the metabolic syndrome predicts incident coronary heart disease and stroke [abstract]. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. The metabolic syndrome as a predictor of type 2 diabetes. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. The impact of the metabolic syndrome and diabetes on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults.

Prevalence of the metabolic syndrome and its relation to all cause and cardiovascular mortality in non-diabetic European men and women. Arch Int Med. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Geneva, World Health Organization, Economics costs of diabetes in U. Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. Rev Psiquiatr Rio Gd Sul.

Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. Causes of the excess mortality of Schizophrenia. Brit J Psychiatry. Newcomer JW. Metabolic disturbances associated with antipsychotic use. Antipsychotic-induced weight gain: a comprehensive research synthesis.

The distribution of body mass index among individuals with and without schizophrenia. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Baptista T.

Body weight gain induced by antipsychotic drug: mechanisms and management. Acta Psychiatr Scand. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. The metabolic syndrome in patients with severe mental illnesses.

Atypical antipsychotics and metabolic dysregulation. J Clin Psychopharmacol. Metabolic syndrome in patients with schizophrenia. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.

Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Meyer JM. Schizophrenia and the metabolic syndrome.

Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Schizophr Res. The prevalence of metabolic syndrome among schizophrenia patients is double that of the general population. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects.

Prospective data from the Verona Diabetes Complications Study. Diabet Med. Guedes EP. In: Godoy-Matos AF, organizador. Mancini MC. In: Lyra R, Cavalcanti N, organizador. Diabetes Mellitus. Rio de Janeiro: Diagraphic Editora; A double-blind, placebo-controlled trial of sibutramine forn olanzapine-associated weight gain. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Dietary Guidelines revision


Todo lo que deberías saber sobre los antipsicóticos

Aim: To compare the prevalence of cardiovascular risk factors CVRF and vascular events, between patients treated and untreated with antipsychotic drugs. Subjects and methods: A cross-sectional study was done in Barcelona. We compared patients attended in Primary Health Care Centres, treated with or without antipsychotics between and Anthropometric measurements, clinical variables, and CVRF were assessed. Adult and elderly patients, typical and atypical antipsychotics, were studied separately. Results: 14, patients had been prescribed antipsychotics We selected 13, patients with the same age and gender but not treated total of 27, patients.


Mecanismos de acción

The use of antipsychotics in patients with dementia. OBJECTIVE: The objective of the present study is to systematically review the supporting evidence for the use of antipsychotics in the treatment of behavioral and psychological symptoms in patients with dementia, as well as the controversies and limitations of this prescription. We discuss the available evidence in the light of the high prevalence of behavioral and psychological symptoms of dementia in this population, along with the greater susceptibility of elderly patients to adverse events. The search was limited to clinical trials and meta-analysis of the literature published from to


Cardiovascular Risk Factors in Chronic Treatment With Antipsychotic Agents Used in Primary Care

This site uses cookies in order to enhance your user experience and customize contents. By continuing to browse the site, you are agreeing to our use of cookies. Share Copy copied. You have exceeded the maximum number of activities that can be shared in Google Classroom for your account type.

Related Articles